Pyxis Oncology

Pyxis Oncology. It is a clinical-stage biotechnology company focused on developing novel therapeutics to treat difficult cancers. The company leverages advanced platforms in antibody-drug conjugate and immunotherapy to build a diversified oncology pipeline. Founded by prominent figures in cancer research, it aims to address significant unmet medical needs in oncology.

Company overview

Pyxis Oncology was established in 2019 by Lara S. Sullivan, a former executive at Pfizer, and the late pioneering oncologist Jose Baselga. The company is headquartered in the biotechnology hub of Cambridge, Massachusetts. Its leadership team includes veterans from major pharmaceutical companies like Bristol Myers Squibb and Merck & Co., bringing extensive experience in drug development and clinical trial design. The corporate mission centers on advancing next-generation treatments that can overcome the limitations of existing cancer therapy.

Pipeline and technology

The company's pipeline is built on two core technology platforms: targeted antibody-drug conjugate and immune-stimulating antibody therapies. Its lead ADC candidate, PYX-201, is an EphA2-targeting agent designed to deliver a potent cytotoxic payload to tumor cells. Another key asset, PYX-106, is a Siglec-15-targeting antibody intended to block an immune checkpoint pathway distinct from PD-1 and PD-L1. These programs originated from strategic research collaborations with institutions like Adimab and were further developed internally. The scientific approach emphasizes targeting novel antigens with validated biology to improve therapeutic indices and patient outcomes.

Clinical trials

Pyxis Oncology has advanced its lead candidates into early-stage human studies. A Phase I trial for PYX-201 is evaluating its safety, pharmacokinetics, and preliminary antitumor activity in patients with select solid tumors. Concurrently, a Phase I/II study is investigating PYX-106 as a monotherapy and in combination with pembrolizumab for advanced solid tumors. These trials are being conducted at multiple research sites across the United States, including major cancer centers. The company follows protocols reviewed by the U.S. Food and Drug Administration and an institutional review board to ensure patient safety and data integrity.

Partnerships and collaborations

The company has established several key strategic partnerships to build and accelerate its pipeline. A foundational collaboration with Adimab provided access to their industry-leading yeast display platform for antibody discovery. Pyxis Oncology also entered into an exclusive license agreement with Pfizer to develop and commercialize the EphA2-targeting ADC program. These alliances complement internal research efforts and provide access to critical intellectual property and technological expertise. The company's business development strategy focuses on selective partnerships that enhance its platform capabilities and therapeutic reach.

Financials and corporate history

Pyxis Oncology completed its initial public offering on the NASDAQ stock exchange in 2021, raising significant capital to fund its operations. Prior to going public, the company secured substantial venture funding from investors including Bain Capital Life Sciences and RA Capital Management. Its financial resources are allocated primarily toward research and development activities, including the ongoing clinical trial programs for PYX-201 and PYX-106. As a pre-revenue company, it operates at a net loss, which is typical for clinical-stage biotechnology firms focused on advancing novel drug candidates through the regulatory process.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:American companies established in 2019